Stiefel Labs, Ex-CEO Cleared Of $2M Securities Fraud Claim

Law360, Miami (November 8, 2013, 8:44 PM EST) -- A federal jury in Miami on Wednesday found that Stiefel Laboratories Inc. and former chief executive Charles Stiefel did not commit securities fraud or breach fiduciary duty in connection with a former executive's sale of company stock ahead of Stiefel's 2009 acquisition by GlaxoSmithKline PLC.

Stiefel has faced several lawsuits, including a failed class action, accusing the pharmaceutical giant of significantly undervaluing its stock and then persuading employees to resell their shares to the company ahead of its sale to Glaxo for $2.9 billion.

“The jury...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Fried v. Stiefel Laboratories, Inc. et al


Case Number

1:11-cv-20853

Court

Florida Southern

Nature of Suit

Labor: E.R.I.S.A.

Judge

Kathleen M. Williams

Date Filed

March 11, 2011

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.